Zhejiang Shouxiangu Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 603896.SS

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. EBT Margin for the year ending December 31, 2023: 32.50%

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. EBT Margin is 32.50% for the year ending December 31, 2023, a -3.06% change year over year. EBT Ratio (Earnings Before Tax Ratio) is the fraction of earnings before taxes to total revenue, indicating the company's profitability before the impact of tax expenses.

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. EBT Margin for the year ending December 31, 2022 was 33.53%, a 27.92% change year over year.
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. EBT Margin for the year ending December 31, 2021 was 26.21%, a 8.46% change year over year.
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. EBT Margin for the year ending December 31, 2020 was 24.17%, a 5.70% change year over year.
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. EBT Margin for the year ending December 31, 2019 was 22.86%, a 6.21% change year over year.

Key data

Date	EBT Margin	Net Income Margin	EBITDA Margin	EBIT Margin

Shanghai Stock Exchange: 603896.SS

Zhejiang Shouxiangu Pharmaceutical Co., Ltd.

CEO	Mr. Zhen-Yu Li
IPO Date	May 10, 2017
Location	China
Headquarters	No. 12, Huanglong Third Road
Employees	1,143
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

Zhejiang Shouxiangu Pharmaceutical Co., Ltd. researches, develops, and sells Chinese medicine products. It offers ganoderma lucidum spore powder, dendrobium officinale, crocus sativus, and other health products. The company was founded in 1997 and is based in Jinhua, China.

Key trends

Past 5 years